Search for Terms or Answers
We take many things for granted. I walked 11,151 steps today going from sessions to posters and exhibit halls to learn as much as I can to take back to my clinic so I can help my patients. My feet were hurting, and my back bothered me as I tried to get comfortable for the next lecture; yet, these minor discomforts are nothing compared to what our patients experience on a daily basis.
Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated.
Even with currently available treatment modalities, ESRD is a common complication of Granulomatosis with polyangiitis (GPA) occurring in approximately 25% of patients. Transplantation frequently used for ESRD but has not been applied widely in GPA.
Clinical trials remain a challenge in SLE and a number of outcome measures have been used with varying success.
Two abstracts in this session sought to address novel ways to assess responses in SLE trials.
A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.
Prof Weyland started by explaining that giant cell arteritis (GCA) and Takayasu Arteritis (TA) are granulomatous forms of arteritis.
The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.
There are two things I learned in rheumatology fellowship.
Never burn any bridges because everyone in rheumatology knows each other
Rheumatologists like their food
Check out this compilation of our ACR Day 1 videocasts merged into one 59 minute podcast !
https://soundcloud.com/rheumnow/rheumnow-acr-2017-san-diego-day-1
Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).
We know that cardiovascular disease (CVD) is the leading cause of death in RA and that traditional risk factors do not fully account for increased risk.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
